Handbook of HER2-targeted agents in breast cancer / by Ricardo H Alvarez, Javier Cortés, Leticia De Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Stefania Zambelli, Dimitrios Zardavas.

Format:

Book

Author/Creator:

Alvarez, Ricardo H., author.

Cortés, Javier (Oncologist), author.

Mattos-Arruda, Leticia De, author.

Falzon, Mary, author.

Fasolo, Angelica, author.

Gandy, Michael, author.

Gianni, Luca, author.

Harbeck, Nadia, author.

Piccart, Martine, author.

Zambelli, Stefania, author.

Zardavas, Dimitrios, author.

Contributor:

SpringerLink (Online service)

Series:

Medicine (Springer-11650)

Language:

English

Subjects (All):

Oncology.

Emergency medicine.

Family medicine.

Internal medicine.

Primary Care Medicine.

General Practice / Family Medicine.

Internal Medicine.

Pharmacotherapy.

Local Subjects:

Oncology.

Primary Care Medicine.

General Practice / Family Medicine.

Internal Medicine.

Pharmacotherapy.

Physical Description:

1 online resource (XI, 96 pages) : 13 illustrations

Contained In:

Springer eBooks

Place of Publication:

Tarporley : Springer Healthcare Limited : Imprint: Springer Healthcare, 2013.

System Details:

text file PDF

Summary:

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.

Contents:

Introduction and background biology

HER2 testing

HER2-positive breast cancer: adjuvant and neoadjuvant therapy

HER2-positive metastatic breast cancer: first-line treatment

HER2-positive metastatic breast cancer: second-line treatment

Emerging targeted agents for HER2-positive breast cancer.

Other Format:

Printed edition:

ISBN:

978-1-907673-94-8

9781907673948

Access Restriction:

Restricted for use by site license.